abs325.txt	randomized	trials	outside	the	u	s		have	found	non-inferior	survival	forneoadjuvant	chemotherapy	(nact)	versus	primary	debulking	surgery	(pds)	foradvanced	ovarian	cancer	(aoc)	however	these	reported	lower	overallsurvival	and	rates	of	optimal	than	studies	leading	toquestions	about	generalizability	to	practice	where	aggressive	ismore	common	consequently	comparative	effectiveness	in	remainscontroversial	we	reviewed	nact	versuspds	for	aoc	here	describe	methodological	challenges	compare	results	totrials	make	suggestions	future	research	identifiedu	published	2010	or	later	that	evaluated	comparativeeffectiveness	pds	on	through	a	pubmed	search	twoindependent	reviewers	abstracted	data	from	eligible	articles	nine	230articles	were	review	included	unmeasuredconfounders	heterogeneous	treatment	effects	variations	over	time	andinconsistent	measurement	whereas	some	limitations	wereunavoidable	several	noted	across	avoidable	includingconditioning	mediating	factors	immortal	introduced	by	measuringsurvival	beginning	diagnosis	without	non-randomizedstudies	are	an	important	source	evidence	ideal	exist	when	assessing	non-randomized	setting	futureobservational	must	ensure	is	consistent	throughout	thestudy	period	groups	comparable	rapidly-evolving	oncologydata	networks	may	allow	identification	intent	otherimportant	confounders
